RxDoctor Payments Data

Eugene Park, MD

Urology · Sioux Falls, SDNPI 1275654782

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,495 of the $2,477 with a category attached, or 60.3%. 15 manufacturers reported payments, led by Coloplast at 43.2% of the total. Reporting peaked in 2022 at $1,895 and has fallen 96.1% since, to $73 in 2025.

$2,477in general payments, 2019–2025

Across 37 payments — averaging $66.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Boston Scientific$932
  • Olympus America Inc.$128
  • Endo Pharmaceuticals Inc.$70
  • EDAP Technomed Inc$66
  • Astellas Pharma US Inc$46
  • plus $166 from 9 others

What the payments were for

  • Travel & lodging$1,49560%
  • Food & beverage$93538%
  • Education$472%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,477 in reported general payments places this provider in the 75th percentile of 40 urology providers in South Dakota.

See all urology providers in South Dakota

Medicare billing

Part B allowed, 2024
$192,600
Medicare patients
558
Services billed
8,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron22$10,092
Tamsulosin Hcl538$7,089
Finasteride361$3,739
Dutasteride101$2,062
Gentamicin Sulfate51$723
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst60$709
Acetaminophen-CodeineAcetaminophen With Codeine118$664
NitrofurantoinNitrofurantoin Macrocrystal19$447
Solifenacin Succinate15$324
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim70$134
Ciprofloxacin Hcl36$83
Levofloxacin49$65
Sodium ChlorideSodium Chloride Irrig Solution28$63
Tramadol Hcl11$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$46$10,09222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 40 urology providers in South Dakota.

Other urology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →